M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs BioSpaceSupernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost...NeuroscienceRead full story pharminent August 3, 2026 (Last updated: August 6, 2026) BioSpace Supernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost… Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Parsortix study shows promise for ADC target detectionNext: AstraZeneca and Bristol Myers Squibb Reported to Have Held Mega-Merger Talks Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
